Of these, EGFR mutation occurs in 55% of Asian patients and 15% of non-Asian patients with lung adenocarcinoma, followed by ALK rearrangement occurs in 5–8%, and other mutations are limited to 5% of non-squamous NSCLC [25, 26]. Here, EGFR is linked to lung adenocarcinoma.